Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy

International Journal of Radiation Oncology Biology Physics

Volumn 58, Issue 3, 2004, Pages 959-965

  Ang, K Kian ^a   Andratschke, Nicolaus H ^a   Milas, Luka ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

EGFR; Head and neck carcinoma; Response therapy

Indexed keywords

AMINO ACIDS; CHEMOTHERAPY; ENZYMES; PATIENT TREATMENT; RADIOTHERAPY; SKIN;

EPIDERMAL GROWTH FACTOR RECEPTORS; TYROSINE KINASE;

TUMORS;

BIOLOGICAL MARKER; CETUXIMAB; CHIMERIC ANTIBODY; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

ACNE; ANOREXIA; ASTHENIA; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; CORRELATION ANALYSIS; DATA ANALYSIS; DESQUAMATION; DIARRHEA; DOSE RESPONSE; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TARGETING; FATIGUE; FEBRILE NEUTROPENIA; FEVER; FOLLICULITIS; HEAD AND NECK CARCINOMA; HEADACHE; HUMAN; LIVER TOXICITY; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FAMILY; PROTEIN TARGETING; RADIATION DOSE; RASH; SKIN MANIFESTATION; SOMNOLENCE; SURVIVAL RATE; VOMITING;

EID: 1242338149     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2003.07.010     Document Type: Conference Paper

References (39)

1. Noonberg S.B., Benz C.C. Tyrosine kinase inhibitors targeted to the epidermal growth factor receptor subfamily. Drugs. 59:2000;753-767.
2. Milas L, Fan Z, Andratschke NH, et al. Epidermal growth factor receptor and tumor response to radiation: In vivo preclinical studies. Int J Radiat Oncol Biol Phys 2004;58:966-971.
3. Grandis J., Tweardy D. Elevated levels of transforming growth factor α and epidermal growth factor receptor messenger RNA are early markers of carcinogenesis in head and neck cancer. Cancer Res. 53:1993;3579-3584.
4. Grandis J.R., Melhem M.F., Barnes E.L., et al. Quantitative immunohistochemical analysis of transforming growth factor-α and epidermal growth factor receptor in patients with squamous cell carcinoma of the head and neck. Cancer. 78:1996;1284-1292.
5. Grandis J.R., Zeng Q., Tweardy D.J. Retinoic acid normalizes the increased gene transcription rate of TGF-alpha and EGFR in head and neck cancer cell lines. Nature Med. 2:1996;237-240.
6. Craven J.M., Pavelic Z.P., Stambrook P.J., et al. Expression of c-erbB-2 gene in human head and neck carcinoma. Anticancer Res. 12:1992;2273-2276.
7. Field JK, Spandidos DA, Yiagnisis M, et al. C-erbB-2 expression in squamous cell carcinoma of the head and neck. Anticancer Res 1992:613-619.
8. Beckhardt R.N., Kiyokawa N., Xi L., et al. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 121:1995;1265-1270.
9. Xia W., Lau Y., Zhang H., et al. Strong correlation between c-erbB-2 overexpression and overall survival of patients with oral squamous cell carcinoma. Clin Cancer Res. 3:1997;3-9.
10. Shintani S., Funaymam T., Yoshihama Y., et al. Prognostic significance of ERRB3 overexpression in oral squamous cell carcinoma. Cancer Lett. 95:1995;79-83.
11. Xia W., Lau Y.K., Zhang H.Z., et al. Combination of EGFR, HER-2/neu and HER-3 is a stronger predictor for the outcome of oral squamous cell carcinoma than any individual family members. Clin Cancer Res. 5:1999;4164-4174.
12. Hendler F., Shum-Siu A., Nanu L., et al. Overexpression of EGF receptors in squamous tumors is associated with poor survival. J Cell Biochem. 12:1988;105.
13. Miyaguchi M., Olofosson J., Hellquist H.B. Expression of epidermal growth factor receptor in glottic carcinoma and its relation to recurrence after radiotherapy. Clin Otolaryngol. 16:1991;466-469.
14. Wen Q.H., Miwa T., Yoshizaki T., et al. Prognostic value of EGFR and TGF-alpha in early laryngeal cancer treated with radiotherapy. Laryngoscope. 106:1996;884-888.
15. Maurizi M., Almadori G., Ferrandina G., et al. Prognostic significance of epidermal growth factor receptor in laryngeal squamous cell carcinoma. Br J Cancer. 74:1996;1253-1257.
16. Dassonville O., Formento J.L., Francoual M., et al. Expression of epidermal growth factor receptor and survival in upper aerodigestive tract cancer. J Clin Oncol. 11:1993;1873-1878.
17. Grandis J., Melhem M., Gooding W., et al. Levels of TGF-α and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst. 90:1998;824-832.
18. Ang K.K., Berkey B., Tu X., et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 62:2002;7350-7356.
19. Cooper J., Farnum N., Asbell S., et al. Recursive partitioning analysis of 2,105 patients treated in RTOG studies of head and neck cancer. Cancer. 77:1996;1905-1911.
20. Sheridan M.T., O'Dwyer T., Seymour C.B., et al. Potential indicators of radiosensitivity in squamous cell carcinoma of the head and neck. Radiat Oncol Invest. 5:1997;180-186.
21. Balaban N., Moni J., Shannon M., et al. The effect of ionizing radiation on signal transduction Antibodies to EGF receptor sensitize A431 cells to radiation . Biochim Biophys Acta. 1314:1996;147-156.
22. Akimoto T., Hunter N.R., Buchmiller L., et al. Inverse relationship between epidermal growth factor receptor expression and radiocurability of murine carcinomas. Clin Cancer Res. 5:1999;437-443.
23. Goldstein N.I., Prewett M., Zuklys K., et al. Biological efficacy of a chimeric antibody to the epidermal growth factor receptor in a human tumor xenograft model. Clin Cancer Res. 1:1995;1311-1318.
24. Hoffmann T., Hafner D., Ballo H., et al. Antitumor activity of anti-epidermal growth factor receptor monoclonal antibodies and cisplatin in ten human head and neck squamous cell carcinoma lines. Anticancer Res. 17:1997;4419-4425.
25. Grandis J.R., Chakraborty A., Melhem M.F., et al. Inhibition of epidermal growth factor receptor gene expression and function decreases proliferation of head and neck squamous carcinoma but not normal mucosal epithelial cells. Oncogene. 15:1997;409-416.
26. Milas L., Mason K., Hunter N., et al. In vivo enhancement of tumor radioresponse by C225 antiepidermal growth factor receptor antibody. Clin Cancer Res. 6:2000;701-708.
27. Nasu S., Ang K.K., Fan Z., et al. C225 antiepidermal growth factor receptor antibody enhances tumor radiocurability. Int J Radiat Oncol Biol Phys. 51:2001;474-477.
28. Huang S.M., Harari P.M. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas Inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis . Clin Cancer Res. 6:2000;2166-2174.
29. Shin D.M., Donato N.J., Perez-Soler R., et al. Epidermal growth factor receptor-targeted therapy with C225 and cisplatin in patients with head and neck cancer. Clin Cancer Res. 7:2001;1204-1213.
30. Fry D.W. Inhibition of the epidermal growth factor receptor family of tyrosine kinases as an approach to cancer chemotherapy Progression from reversible to irreversible inhibitors . Pharmacol Ther. 82:1999;207-218.
31. He Y., Zeng Q., Drenning S.D., et al. Inhibition of human squamous cell carcinoma growth in vivo by epidermal growth factor receptor antisense RNA transcribed from the U6 promoter. J Natl Cancer Inst. 90:1998;1080-1087.
32. Contessa J.N., Reardon D.B., Todd D., et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. Clin Cancer Res. 5:1999;405-411.
33. Hidalgo M., Siu L.L., Nemunaitis J., et al. Phase I and pharmacological study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol. 19:2001;3267-3279.
34. Senzer N., Soulieres D., Siu L., et al. Phase 2 evaluation of OSI-774, a potent oral antagonist of the EGFR-TK in patients with advanced squamous cell carcinoma of the head and neck. Proc ASCO. 20:2001;2a.
35. Baselga J., Rischin D., Ranson M., et al. Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types. J Clin Oncol. 20:2002;4292-4302.
36. Cohen E.E.W., Rosen F., Dekker A., et al. Phase II study of ZD 1839 (Iressa) in recurrent of metastatic squamous cell carcinoma of the head and neck (SCCHN). Proc ASCO. 21:2002;225a.
37. Burtness B.A., Li Y., Flood W., et al. Phase III trial comparing cisplatin (C) + placebo (P) + anti-epidermal growth factor antibody (EGF-R) C225 in patients (pts) with metastatic/recurrent head and neck cancer (HNC). Proc ASCO. 21:2002;226a.
38. Forouzesh B., Hidalgo M., Takimoto C., et al. Phase I, pharmacokinetic (PK), and biological studies of the epidermal growth factor-tyrosine kinase (EGFR-TK) inhibitor OSI-774 in combination with docetaxel. Proc ASCO. 21:2002;21a.
39. Robert F., Ezekiel M.P., Spencer S.A., et al. Phase I study of anti-epidermal growth factor receptor antibody cetuximab in combination with radiation therapy in patients with advanced head and neck cancer. J Clin Oncol. 19:2001;3234-3243.